Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 153, Issue 5, Pages 545-556
Publisher
Wiley
Online
2011-04-18
DOI
10.1111/j.1365-2141.2011.08676.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
- (2010) M. Suljagic et al. BLOOD
- CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia
- (2010) F. T. Liu et al. BLOOD
- The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment
- (2010) A. J. Steele et al. BLOOD
- Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia
- (2010) L. R. Martins et al. BLOOD
- Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia
- (2010) M. Shehata et al. BLOOD
- The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
- (2010) M. Hudecek et al. BLOOD
- Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
- (2010) A. P. Bhatt et al. BLOOD
- 17-DMAG targets the nuclear factor- B family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
- (2010) E. Hertlein et al. BLOOD
- Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
- (2010) M. Buchner et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia
- (2010) N. Capitani et al. BLOOD
- Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF- B Activation and De novo Gene Transcription
- (2010) A. G. S. Buggins et al. CANCER RESEARCH
- Novel dual Src/Abl inhibitors for hematologic and solid malignancies
- (2010) Silvia Schenone et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells
- (2010) M. Baou et al. HAEMATOLOGICA
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
- (2010) C A Sparks et al. ONCOGENE
- Addiction to protein kinase CK2: A common denominator of diverse cancer cells?
- (2009) Maria Ruzzene et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia
- (2009) M. Herling et al. BLOOD
- Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
- (2009) M. Niedermeier et al. BLOOD
- 2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells
- (2009) A. J. Steele et al. BLOOD
- PKC is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC as a therapeutic target in chronic lymphocytic leukemia
- (2009) C. Holler et al. BLOOD
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
- (2009) Rong Chen et al. BLOOD
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
- (2009) R. Lapalombella et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
- (2009) Kristie A. Blum et al. BRITISH JOURNAL OF HAEMATOLOGY
- Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
- (2009) Maike Buchner et al. CANCER RESEARCH
- p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective I B Kinase Inhibitor BMS-345541
- (2009) M. Lopez-Guerra et al. CLINICAL CANCER RESEARCH
- Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG
- (2009) A. K. Ghosh et al. CLINICAL CANCER RESEARCH
- Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition
- (2009) J. Zhuang et al. HAEMATOLOGICA
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia
- (2009) Tait D. Shanafelt et al. JOURNAL OF CLINICAL ONCOLOGY
- Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia
- (2009) Saman Hewamana et al. JOURNAL OF CLINICAL ONCOLOGY
- Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia
- (2009) A Sanchez-Aguilera et al. LEUKEMIA
- A Small Molecule Inhibitor of Inducible Heat Shock Protein 70
- (2009) J. I-Ju Leu et al. MOLECULAR CELL
- Molecular and cellular mechanisms of CLL: novel therapeutic approaches
- (2009) Lisa Pleyer et al. Nature Reviews Clinical Oncology
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression
- (2009) A D Baudot et al. ONCOGENE
- State-of-the-art treatment of chronic lymphocytic leukemia
- (2009) M. Hallek Hematology-American Society of Hematology Education Program
- A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
- (2008) Thomas Decker et al. ANNALS OF HEMATOLOGY
- c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
- (2008) D. Y. H. Hallaert et al. BLOOD
- Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia
- (2008) L. Trentin et al. BLOOD
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- The NF- B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
- (2008) S. Hewamana et al. BLOOD
- Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
- (2008) M. Muzio et al. BLOOD
- The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes
- (2008) A. Veldurthy et al. BLOOD
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
- (2008) M. A. Phelps et al. BLOOD
- The Novel Nuclear Factor- B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine
- (2008) S. Hewamana et al. CLINICAL CANCER RESEARCH
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
- (2008) D. A. Rizzieri et al. CLINICAL CANCER RESEARCH
- Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Baskar et al. CLINICAL CANCER RESEARCH
- A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
- (2008) Peter Gimsing et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
- (2008) Amir H. DaneshManesh et al. INTERNATIONAL JOURNAL OF CANCER
- Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division
- (2008) A Poggi et al. LEUKEMIA
- Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells
- (2008) S Inoue et al. LEUKEMIA
- Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
- (2008) L S Steelman et al. LEUKEMIA
- Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
- (2008) S Gobessi et al. LEUKEMIA
- Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination
- (2008) Anna Åleskog et al. LEUKEMIA & LYMPHOMA
- Is NF-κB a good target for cancer therapy? Hopes and pitfalls
- (2008) Véronique Baud et al. NATURE REVIEWS DRUG DISCOVERY
- The RSK family of kinases: emerging roles in cellular signalling
- (2008) Rana Anjum et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PI3K/Akt: getting it right matters
- (2008) T F Franke ONCOGENE
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a
- (2008) T. Fukuda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation